Search Page

1

Cite

Share

Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancers.

Cottini F, Hideshima T, Xu C, Sattler M, Dori M, Agnelli L, ten Hacken E, Bertilaccio MT, Antonini E, Neri A, Ponzoni M, Marcatti M, Richardson PG, Carrasco R, Kimmelman AC, Wong KK, Caligaris-Cappio F, Blandino G, Kuehl WM, Anderson KC, Tonon G. Cottini F, et al. Nat Med. 2014 Jun;20(6):599-606. doi: 10.1038/nm.3562. Epub 2014 May 11. Nat Med. 2014. PMID: 24813251 Free PMC article.

Cite

Share

2

Cite

Share

CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications.

Tai YT, Landesman Y, Acharya C, Calle Y, Zhong MY, Cea M, Tannenbaum D, Cagnetta A, Reagan M, Munshi AA, Senapedis W, Saint-Martin JR, Kashyap T, Shacham S, Kauffman M, Gu Y, Wu L, Ghobrial I, Zhan F, Kung AL, Schey SA, Richardson P, Munshi NC, Anderson KC. Tai YT, et al. Leukemia. 2014 Jan;28(1):155-65. doi: 10.1038/leu.2013.115. Epub 2013 Apr 16. Leukemia. 2014. PMID: 23588715 Free PMC article.

Cite

Share

3

Cite

Share

Characterization of the MM.1 human multiple myeloma (MM) cell lines: a model system to elucidate the characteristics, behavior, and signaling of steroid-sensitive and -resistant MM cells.

Greenstein S, Krett NL, Kurosawa Y, Ma C, Chauhan D, Hideshima T, Anderson KC, Rosen ST. Greenstein S, et al. Exp Hematol. 2003 Apr;31(4):271-82. doi: 10.1016/s0301-472x(03)00023-7. Exp Hematol. 2003. PMID: 12691914 Review.

Cite

Share

4

Cite

Share

Multiple myeloma.

Anderson KC, Shaughnessy JD Jr, Barlogie B, Harousseau JL, Roodman GD. Anderson KC, et al. Hematology Am Soc Hematol Educ Program. 2002:214-40. doi: 10.1182/asheducation-2002.1.214. Hematology Am Soc Hematol Educ Program. 2002. PMID: 12446425 Review.

Cite

Share

5

Cite

Share

New frontiers in the treatment of multiple myeloma.

Hwang JJ, Ghobrial IM, Anderson KC. Hwang JJ, et al. ScientificWorldJournal. 2006 Dec 6;6:1475-503. doi: 10.1100/tsw.2006.236. ScientificWorldJournal. 2006. PMID: 17160337 Free PMC article. Review.

Cite

Share

6

Cite

Share

The KDM3A-KLF2-IRF4 axis maintains myeloma cell survival.

Ohguchi H, Hideshima T, Bhasin MK, Gorgun GT, Santo L, Cea M, Samur MK, Mimura N, Suzuki R, Tai YT, Carrasco RD, Raje N, Richardson PG, Munshi NC, Harigae H, Sanda T, Sakai J, Anderson KC. Ohguchi H, et al. Nat Commun. 2016 Jan 5;7:10258. doi: 10.1038/ncomms10258. Nat Commun. 2016. PMID: 26728187 Free PMC article.

Cite

Share

7

Cite

Share

Novel biological therapies for the treatment of multiple myeloma.

Richardson PG, Mitsiades CS, Hideshima T, Anderson KC. Richardson PG, et al. Best Pract Res Clin Haematol. 2005;18(4):619-34. doi: 10.1016/j.beha.2005.01.010. Best Pract Res Clin Haematol. 2005. PMID: 16026741 Review.

Cite

Share

8

Cite

Share

The emerging role of novel therapies for the treatment of relapsed myeloma.

Richardson PG, Hideshima T, Mitsiades C, Anderson KC. Richardson PG, et al. J Natl Compr Canc Netw. 2007 Feb;5(2):149-62. doi: 10.6004/jnccn.2007.0015. J Natl Compr Canc Netw. 2007. PMID: 17335684 Review.

Cite

Share

9

Cite

Share

Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications.

Mitsiades CS, Mitsiades N, Poulaki V, Schlossman R, Akiyama M, Chauhan D, Hideshima T, Treon SP, Munshi NC, Richardson PG, Anderson KC. Mitsiades CS, et al. Oncogene. 2002 Aug 22;21(37):5673-83. doi: 10.1038/sj.onc.1205664. Oncogene. 2002. PMID: 12173037

Cite

Share

10

Cite

Share

Intracellular NAD⁺ depletion enhances bortezomib-induced anti-myeloma activity.

Cagnetta A, Cea M, Calimeri T, Acharya C, Fulciniti M, Tai YT, Hideshima T, Chauhan D, Zhong MY, Patrone F, Nencioni A, Gobbi M, Richardson P, Munshi N, Anderson KC. Cagnetta A, et al. Blood. 2013 Aug 15;122(7):1243-55. doi: 10.1182/blood-2013-02-483511. Epub 2013 Jul 3. Blood. 2013. PMID: 23823317 Free PMC article.

Cite

Share